Multikinase inhibitors use in differentiated thyroid carcinoma

por Jasim, Sina, Ozsari, Levent, Habra, Mouhammed Amir
Publicado 2014

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options

por Al-Ward, Ruaa, Zsembery, Celeste, Habra, Mouhammed Amir
Publicado 2022

Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions

por Bedrose, Sara, Daher, Marilyne, Altameemi, Lina, Habra, Mouhammed Amir
Publicado 2020

Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study

por Shawa, Hassan, Deniz, Ferhat, Bazerbashi, Hadil, Hernandez, Mike, Vassilopoulou-Sellin, Rena, Jimenez, Camilo, Habra, Mouhammed Amir
Publicado 2013

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?

por Jimenez, Camilo, Armaiz-Pena, Gustavo, Dahia, Patricia L. M., Lu, Yang, Toledo, Rodrigo A., Varghese, Jeena, Habra, Mouhammed Amir
Publicado 2022

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models

por Bagby, Stacey, Foust, Lindsey, Habra, Mouhammed Amir, Kiseljak-Vassiliades, Katja, Pitts, Todd, Pozdeyev, Nikita, Wierman, Margaret E, Kar, Adwitiya
Publicado 2022

The prevalence and spectrum of reported incidental adrenal abnormalities in abdominal computed tomography of cancer patients: The experience of a comprehensive cancer center

por Qdaisat, Aiham, Bedrose, Sara, Ezzeldin, Obadah, Moawad, Ahmed W., Yeung, Sai-Ching J., Elsayes, Khaled M., Habra, Mouhammed Amir
Publicado 2022

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical...

por Habra, Mouhammed Amir, Hammer, Gary D, Kebebew, Electron, Worden, Francis P, Raj, Nitya, Hallanger-Johnson, Julie E, Grauer, Andreas, Moraitis, Andreas
Publicado 2021

The Immunotherapy Landscape in Adrenocortical Cancer

por Pegna, Guillaume J., Roper, Nitin, Kaplan, Rosandra N., Bergsland, Emily, Kiseljak-Vassiliades, Katja, Habra, Mouhammed Amir, Pommier, Yves, Del Rivero, Jaydira
Publicado 2021

SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma

por Bedrose, Sara Shokry Daniel, Altameemi, Lina, Daher, Marilyne, De Rosa, Gina Tamsen, Varghese, Jeena Mary, Jimenez, Camilo, Campbell, Matthew, Habra, Mouhammed Amir
Publicado 2020

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study

por Kimpel, Otilia, Bedrose, Sara, Megerle, Felix, Berruti, Alfredo, Terzolo, Massimo, Kroiss, Matthias, Mai, Knut, Dekkers, Olaf M., Habra, Mouhammed Amir, Fassnacht, Martin
Publicado 2021

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas

por Jimenez, Camilo, Subbiah, Vivek, Stephen, Bettzy, Ma, Junsheng, Milton, Denai, Xu, Mingxuan, Zarifa, Abdualrazzak, Akhmedzhanov, Fechukwu Omolara, Tsimberidou, Apostolia, Habra, Mouhammed Amir, Rodon Anhert, Jordi, Fu, Siqing, Naing, Aung
Publicado 2020

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib

por Taylor, Matthew H., Takahashi, Shunji, Capdevila, Jaume, Tahara, Makoto, Leboulleux, Sophie, Kiyota, Naomi, Dutcus, Corina E., Xie, Ran, Robinson, Bruce, Sherman, Steven, Habra, Mouhammed Amir, Elisei, Rossella, Wirth, Lori J.
Publicado 2021

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

por Iyer, Priyanka C., Dadu, Ramona, Gule-Monroe, Maria, Busaidy, Naifa L., Ferrarotto, Renata, Habra, Mouhammed Amir, Zafereo, Mark, Williams, Michelle D., Gunn, G. Brandon, Grosu, Horiana, Skinner, Heath D., Sturgis, Erich M., Gross, Neil, Cabanillas, Maria E.
Publicado 2018

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

por Bedrose, Sara, Miller, Kevin Charles, Altameemi, Lina, Ali, Mohamed S, Nassar, Sameh, Garg, Naveen, Daher, Marilyne, Eaton, Keith D, Yorio, Jeffrey Thomas, Daniel, Davey B, Campbell, Matthew, Bible, Keith C, Ryder, Mabel, Chintakuntlawar, Ashish V, Habra, Mouhammed Amir
Publicado 2020

Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns

por Nguyen, Ha, Shah, Komal, Waguespack, Steven G, Hu, Mimi I, Habra, Mouhammed Amir, Cabanillas, Maria E, Busaidy, Naifa L, Bassett, Roland, Zhou, Shouhao, Iyer, Priyanka C, Simmons, Garrett, Kaya, Diana, Pitteloud, Marie, Subudhi, Sumit K, Diab, Adi, Dadu, Ramona
Publicado 2021

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

por Habra, Mouhammed Amir, Stephen, Bettzy, Campbell, Matthew, Hess, Kenneth, Tapia, Coya, Xu, Mingxuan, Rodon Ahnert, Jordi, Jimenez, Camilo, Lee, Jeffrey E., Perrier, Nancy D., Boraddus, Russell R., Pant, Shubham, Subbiah, Vivek, Hong, David S., Zarifa, Abdulrazzak, Fu, Siqing, Karp, Daniel D., Meric-Bernstam, Funda, Naing, Aung
Publicado 2019